May 21, 2024 06:42 GMT
Glaxo: Positive Phase III For Asthma Drug
HEALTHCARE
Glaxo (GSK: A2/A): Positive Results in Phase III Asthma Trial
Glaxo today announced positive results for Depemokimab
- Targeting £3b Peak Annual sales.
- This would be a very significant drug. As a guide their leading revenue source (Shingrix) makes £3.4b per year.
- Respiratory health in total sells £11b
{https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-results-from-phase-iii-severe-asthma-trials-of-depemokimab/}
Keep reading...Show less
47 words